Aldeyra Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Aldeyra Therapeutics is a biopharmaceutical company developing treatments for immune-mediated and inflammatory diseases, including dry eye disease and other ocular and systemic conditions, with its lead product candidate reproxalap targeting aldehyde-mediated inflammation.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| DOUGLAS RICHARDDirector | Buy | $129K | 200,000at $0.64 | Nov 11, 2026 |
| Alfieri MichaelPrincipal Financial Officer | Buy | $7K | 10,000at $0.65 | Nov 11, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ALDX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.